Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619775 · ClinicalTrials.gov registry record · Phase 3
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
A Phase 3 study of Carotid Artery Disease, sponsored by Medtronic Endovascular.
- Completed
- Registry status
- Phase 3
- Development phase
- 419
- Enrollment target
- 20
- Study locations
NCT00619775 is a Phase 3 study of Carotid Artery Disease that has completed, run by Medtronic Endovascular. The registered enrollment target is 419 participants, below the 13,649-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00619775, a Phase 3 study of Carotid Artery Disease, has completed, sponsored by Medtronic Endovascular.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 419 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate the safety and efficacy of the Protege Stent and Spider Device in the treatment of common and/or internal carotid artery stenoses for subjects that are high risk for carotid endarterectomy.
Conditions Studied
Interventions
- DEVICE PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device
Study Locations (20)
California
- Scripps Memorial Hospital - La Jolla
- El Camino Hospital - Mountain View
- Hoag Memorial Hospital - Newport Beach
- Salinas Valley Memorial Healthcare System - Salinas
Indiana
- St. Vincent Hospital & Health Care Centers - Indianapolis
- The Heart Center of Indiana - Indianapolis
Louisiana
- Terrebonne General Hospital - Houma
- Southwest Medical Center - Lafayette
Maryland
- Union Memorial Hospital - Baltimore
- Washington Adventist Hospital - Takoma Park
Michigan
- Oakwood Hospital - Dearborn
- William Beaumont Hospital - Royal Oak
North Carolina
- Duke University Medical Center - Raleigh
- Wake Heart Associates - Raleigh
Arizona
- Banner Baywood Heart Hospital - Mesa
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619775
The ClinicalTrials.gov registry entry for NCT00619775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 13,649-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (97% lower). The listed sponsor is Medtronic Endovascular, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carotid Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device is the first listed.
NCT00619775 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Indiana, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00619775 about?
NCT00619775 is a clinical study titled "Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial". Evaluate the safety and efficacy of the Protege Stent and Spider Device in the treatment of common and/or internal carotid artery stenoses for subjects that are high risk for carotid endarterectomy.
What is the current status of trial NCT00619775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2004-04. Estimated completion is 2005-10.
What conditions does trial NCT00619775 study?
This clinical trial studies the following conditions: Carotid Artery Disease.
What interventions are being tested in trial NCT00619775?
The interventions under investigation include: PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device (DEVICE).
Who is sponsoring clinical trial NCT00619775?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00619775 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carotid Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVS VQI TransCarotid Revascularization Surveillance Project
RECRUITING
-
The Gore SCAFFOLD Clinical Study
COMPLETED · NA
-
CAPTURE 2 Post-Marketing Registry
COMPLETED
-
Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study
COMPLETED · NA
-
Assessment Of Vascular Health After Niacin Therapy (AVANT)
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.